Objective The aim of this study was to assess the relationship between the duration of diabetes and the physiological serum bilirubin concentration in association with antioxidant properties in patients with type 2 diabetes. Methods A total of 1,746 patients with type 2 diabetes were investigated in this cross-sectional study. An analysis of covariance was performed after adjusting for other covariates. Simple correlation analyses and a multivariate regression model were used to assess the association between the duration of diabetes and the serum bilirubin concentration. Results The mean total bilirubin value differed significantly according to the tertile of diabetes duration (<5 years, 12.38 μmol/L, 95% confidence interval (CI) 12.02-12.76; 5-11.9 years, 12.33 μmol/L, 95% CI 11.97-12.69 ! 12 years, 11.73 μmol/L, 95% CI 11.35-12.11; p for trend =0.033), after adjustment for other covariates. In addition, an inverse correlation was found between the serum bilirubin concentration and diabetes duration (ρ=-0.211, p<0.001). According to a multivariate model, the association between the diabetes duration and serum bilirubin concentration remained significant, even after adjustment for confounding factors (β=-0.074, p=0.008). Conclusion The duration of diabetes is inversely associated with a serum bilirubin concentration within the physiologic range in patients with type 2 diabetes.
Introduction
Bilirubin is the natural end product of heme metabolism and a potent endogenous antioxidant and cytoprotectant (1) . Although severe hyperbilirubinemia causes neurotoxicity, a normal to modestly elevated bilirubin level has been suggested to play a beneficial role in preventing oxidative stress-related disorders (2) . In addition, oxidized low-density lipoprotein is involved in the atherosclerotic process (3) , and bilirubin is an effective antioxidant that effectively scavenges peroxyl radicals and inhibits the oxidation of lipoproteins against atherosclerosis (2, 3) . Previous clinical studies have shown that the total bilirubin level is inversely associated with the incidence of cardiovascular disease, stroke and peripheral arterial disease, indicating that an elevated serum bilirubin concentration provides protection against atherosclerotic disease (2, 4, 5) .
Oxidative stress is related to the pathogenesis of type 2 diabetes (6). Recently, several clinical studies have reported an inverse relationship between the serum bilirubin level and diabetic microangiopathy (2) . Therefore, a decrease of the serum bilirubin level and its antioxidant properties may result in an additional risk for the development of macro-and microangiopathy in patients with type 2 diabetes. There is evidence that the expression of heme oxygenase-1 (HO-1), an enzyme that breaks down heme into bilirubin, may be altered as diabetes progresses, suggesting that diabetes itself influences the serum bilirubin concentration (7) (8) (9) . However, the relationship between the physiological serum bilirubin level and the duration of diabetes in patients with type 2 diabetes has not been fully clarified.
In the present study, we investigated the relationship between the diabetes duration and a serum bilirubin level within the physiologic range in patients with type 2 diabetes.
Materials and Methods

Subjects
This study was conducted from July 2011 to December 2012. A total of 1,746 patients with type 2 diabetes were randomly selected from among patients who visited the diabetes clinic of our hospital in this cross-sectional study. History and physical examinations, including measurements of blood pressure, height and body weight, were conducted. Body mass index (BMI) was calculated as weight (kg) divided by the square of height (m 2 ). Waist circumference was measured to the nearest 0.1 cm at the narrowest point between the lower limit of the ribcage and the iliac crest. Hypertension was diagnosed based on a blood pressure greater than 140/90 mmHg or the use of antihypertensive drugs. Antihypertensive medications were classified as inhibitors of the renin-angiotensin system (RAS inhibitors) or other antihypertensive drugs (diuretics, beta blockers, calcium channel blockers, etc.). RAS inhibitors included angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers. Clinical data regarding the duration of diabetes, alcohol consumption, cigarette smoking and other healthrelated variables were obtained using a standardized questionnaire. Patients with advanced renal dysfunction (a serum creatinine level greater than 176 μmol/L), malignant disease, thyrotoxicosis, genetic or chronic liver disease including Gilbert's syndrome, viral hepatitis B or C, liver cirrhosis, pancreatitis, infection, heart failure or hematologic disease were excluded. Patients using glucocorticoids, methyltestosterone, oral contraceptives, phenobarbital, allopurinol or anti-inflammatory drugs were excluded. Subjects with a serum bilirubin concentration above the upper normal limit of 22.23 μmol/L and those with a serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level above the upper limit of the normal range (i.e., >37 U/L) were also excluded. The study was approved by the local ethics committee, and all participants provided their informed consent.
Measurements
Blood samples were taken after an overnight fast. The level of glycated hemoglobin (HbA1c) was measured with ion exchange liquid chromatography using a model HLC-723-GHbV apparatus (Tosoh, Tokyo, Japan). The levels of total cholesterol, high-density lipoprotein cholesterol (HDLcholesterol), and triglycerides were measured using an AU 5400 device (Olympus, Tokyo, Japan). The serum bilirubin levels were measured according to an enzymatic method with bilirubin oxidase on a model AU5407 automatic analyzer (Olympus). The normal range for the serum total bilirubin level used in the study was 3.76-22.23 μmol/L. The serum levels of AST and ALT were also determined using the AU5407 analyzer, while the serum levels of gammaglutamyl transpeptidase (γ-GTP) were assessed using a model AU5200 automated analyzer (Olympus). The level of urinary albumin excretion was calculated in random urine samples based on the urinary albumin-creatinine (Cr) ratio (UACR). The urinary albumin concentration was measured using an immunoturbidimetric commercial kit (Randox, Antrim, UK). The estimated glomerular filtration rate (eGFR) was calculated according to the equation reported in the Modification of Diet in Renal Disease study (MDRD) (10) . Nephropathy was defined as a UACR of ! 300 mg/gCr or eGFR of <60 mL/min per 1.73 m 2 . To assess the degree of retinopathy, an ophthalmologist performed fundoscopy following pupil dilation. Peripheral sensory neuropathy was defined as a vibration perception threshold of ! 25 V or the inability to feel a 10-g Semmes-Weinstein monofilament (11) . Coronary heart disease and cerebrovascular disease were both defined as cardiovascular disease (CVD). A diagnosis of coronary heart disease was made based on a history of myocardial infarction, angina pectoris or ischemic heart disease, coronary artery angioplasty or the findings of a pathological electrocardiogram according to the Minnesota code (12) . Cerebrovascular disease was considered to be present if diagnosed according to medical records and/or if a pathological finding was registered on computed tomography or magnetic resonance imaging of the brain (13) .
Statistical analyses
The data are expressed as the mean ± SD or frequency. The bilirubin level and diabetes duration were divided into tertiles. Tests for linear trends across increasing categories of the serum bilirubin concentration treated categories as continuous variables in the model. The linear-by linear association test was used for qualitative variables. Relationships between the serum bilirubin concentration and the duration of diabetes or other variables were examined according to Spearman's rank correlation analyses. An analysis of covariance (ANCOVA) was performed to compare the mean bilirubin level according to the tertile of diabetes duration. Multiple linear regression models were used to determine the association between the serum bilirubin concentration and the diabetes duration. The identified independent variables and factors that have been previously reported to have independent associations were included as covariates. Liver function test variables were also considered as covariates. Oral hypoglycemic agent (OHA) and insulin use was coded as a dummy variable in the adjustment for antidiabetic medications. In addition, two dummy variables were considered for antihypertensive medications, including RAS inhibitors and other antihypertensive drugs (diuretics, beta block- ers, calcium channel blockers, etc.). Model 1 was adjusted for age and gender. Model 2 included the model 1 variables plus smoking habits, alcohol consumption, BMI, hemoglobin, AST and ALT. Model 3 included all of the model 2 variables plus HbA1c, total cholesterol, systolic blood pressure, statin use, antihypertensive medications and antidiabetic therapy. The statistical analyses were performed using the SPSS software package, version 17.0 (SPSS, Chicago, USA). A p value of <0.05 was considered to be statistically significant.
Results
The clinical characteristics of the subjects with type 2 diabetes in this study are summarized in Table 1 . The mean age of the subjects was 61.4±11.5 years. The mean duration of diabetes and level of HbA1c were 9.6±8.1 years and 69±24 mmol/mol (8.4±2.2%), respectively. The mean total bilirubin concentration was 12.38±4.24 μmol/L. The total cholesterol, HDL-cholesterol, AST, ALT and hemoglobin levels tended to be higher in the patients with an increased total bilirubin level. These subjects were more frequently men. Age, diabetes duration, HbA1c, triglycerides, creatinine, smoking habits, and the prevalence of hypertension, diabetic retinopathy, nephropathy, peripheral sensory neuropathy and cardiovascular disease tended to be lower in the subjects with an increased total bilirubin level.
The Spearman's rank correlation coefficients between the serum bilirubin level and the other variables are shown in Table 2 . An inverse correlation was found between the serum bilirubin concentration and the diabetes duration (ρ=-0.211, p<0.001). The levels of hemoglobin, ALT and HDLcholesterol were positively associated with the serum concentration of bilirubin, whereas an inverse correlation was found between the serum bilirubin level and age. Linear regression models were used to determine the association between the diabetes duration and the serum bilirubin concentration (Table 4 ). There was a significant association between the duration of diabetes and the serum bilirubin concentration, following adjustment for variables including age, gender, BMI, smoking habits, alcohol consumption, AST, ALT, hemoglobin, HbA1c, total cholesterol, systolic blood pressure, statin use, antihypertensive medications and antidiabetic therapy (β=-0.074, p=0.008).
Discussion
In the present study, our results showed the physiological serum bilirubin concentrations to be inversely associated with the duration of diabetes in patients with type 2 diabetes. Therefore, our data suggest that the physiological serum bilirubin level, with its associated antioxidant properties, declines as the duration of diabetes increases, although the causative nature of the relationship could not be determined in this study.
Bilirubin is a potent endogenous anti-oxidant (1). Heme oxygenase catalyzes the degradation of heme to carbon monoxide, free iron, and biliverdin, which is rapidly converted to bilirubin by biliverdin reductase (1). When bilirubin scavenges oxidants, bilirubin is re-converted to biliverdin, although biliverdin reductase rapidly regenerates bilirubin, resulting in an increased antioxidant potential (1).
All forms of bilirubin, including free bilirubin, albuminbound bilirubin, conjugated bilirubin and unconjugated bilirubin, are effective antioxidants (14, 15) . The serum bilirubin concentration is directly correlated with the serum antioxidant capacity (2) . In addition, bilirubin plays a protective role in the inflammatory process in the vasculature (16) . Hence, it has been suggested that a normal to mildly elevated serum bilirubin level is a protective biomarker against oxidative stress-mediated diseases (2) .
The serum bilirubin concentration may be associated with the metabolic milieu. Diabetes mellitus is consistently associated with increased oxidative stress (6) . Several clinical studies have reported that the serum bilirubin level is negatively associated with the prevalence of type 2 diabetes (17, 18) , suggesting the potential effect of a lower serum bilirubin concentration on the risk of diabetes. Furthermore, our results showed that the duration of diabetes is independently and inversely associated with the physiological serum bilirubin concentration, suggesting that the serum bilirubin level, with its associated antioxidant properties, declines with an increasing duration of diabetes after the development of type 2 diabetes. Smoking is also associated with a decreased serum bilirubin level (19) , and several clinical studies have reported that the serum bilirubin level is associated with the prevalence of hypertension, HbA1c, and dyslipidemia (18, 20, 21) . In the present study, the serum bilirubin level was also found to be associated with age, smoking habits, HbA1c, the lipid profile and hypertension. However, in the multivariate analysis, the relationship between the bilirubin level and the duration of diabetes remained statistically significant, even after adjusting for confounding factors, including age, gender, smoking habits, alcohol consumption, BMI, systolic blood pressure, hemoglobin, total cholesterol, HbA1c, statin use, antihypertensive medications, antidiabetic therapy and the associated liver function, indicating that these factors did not significantly affect the relationship between bilirubin and the diabetes duration.
There are several plausible explanations for the association between the bilirubin level and the duration of diabetes. Most serum bilirubin results from the catabolism of hemoglobin in reticuloendothelial cells (22) . A low hemoglobin concentration is also common in patients with diabetes (23) . In addition to the development of a decreased hemoglobin level in patients with an impaired renal function or albuminuria (24) , several clinical studies have shown an ongoing decline in the hemoglobin level over time in patients with type 2 diabetes, even in the presence of a normal renal function and normoalbuminuria (23) . Therefore, because hemoglobin degradation is the main source of bilirubin, it is expected that the bilirubin concentration will decrease as the hemoglobin level decreases. This hypothesis is partly supported by the recent findings of Fukui et al. (25) , who reported that the serum total bilirubin concentrations are lower in hemodialysis patients than in those treated without hemodialysis among subjects with type 2 diabetes, as a decreased hemoglobin level is frequently associated with an impaired renal function in patients with diabetes (24) . However, in the present multivariate analysis, the association between the diabetes duration and the serum bilirubin level remained statistically significant after adjustment for confounding factors, including the hemoglobin level, suggesting that additional mechanisms exist. Another possible explanation involves variation of the HO-1 expression at different stages of diabetes, with a decrease observed in the late stage of the disease (7, 8) . HO is the rate-limiting enzyme in the catabolism of heme (1) . In a hyperglycemic rat model, chronic hyperglycemia results in a decrease in the HO activity (26) , while down-regulation of the HO activity inhibits bilirubin production (27) . Therefore, chronic hyperglycemia of a long duration may result in a decrease in bilirubin production. Finally, chronic hyperglycemia can lead to the activation of oxidative stress and increased production of reactive oxygen species, which may ultimately result in the depletion of antioxidants (28) . However, the exact mechanisms for this causal role remain to be clarified.
The incidence of diabetic microvascular complications increases with an increasing duration of diabetes in patients with type 2 diabetes (29) . The duration of diabetes is also independently associated with the risk of ischemic stroke (30) . The incidence of coronary heart disease and death due to cardiovascular disease increases with the duration of diabetes in patients with type 2 diabetes (29). Previous clinical studies have reported that the serum bilirubin concentration is inversely associated with the carotid intimamedia thickness, coronary heart disease, peripheral arterial disease and stroke (2, 4, 5) . Recently, several clinical studies have demonstrated a negative relationship between the serum bilirubin level and urinary albumin excretion in patients with type 2 diabetes (2, 31). In addition, Yasuda et al. (32) reported that the serum total bilirubin level correlates inversely with the prevalence of diabetic retinopathy. In the present study, the prevalence of diabetic microvascular complications and cardiovascular disease tended to be lower in the subjects with an increased total bilirubin level, consistent with the findings of previous studies (2, 4, 31, 32 ). Therefore, our results suggest that the inverse association between the diabetes duration and bilirubin is supported by an additional pathway linking diabetes to an increased vascular burden along with an increasing duration of diabetes. Therefore, prospective studies assessing the relationship between bilirubin and chronic complications with respect to an increasing duration of diabetes in patients with type 2 diabetes are warranted.
The present study is associated with some limitations. As the design of this study was cross-sectional, the causative nature of the association between the duration of diabetes and the serum bilirubin level cannot be established. Additionally, our data do not provide longitudinal information regarding changes in the serum bilirubin level over time in patients with type 2 diabetes. Despite these limitations, our findings offer important information regarding the relation-ship between the diabetes duration and the serum bilirubin concentration with respect to antioxidant properties.
In conclusion, our results showed the duration of diabetes to be inversely associated with a serum bilirubin concentration within the physiologic range in patients with type 2 diabetes. Further investigations are needed to assess the causal role of bilirubin with respect to the natural course of disease observed in patients with type 2 diabetes over time.
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